News | Proton Therapy | April 25, 2019

California Protons Cancer Therapy Center Begins Breast Cancer Study Enrollment

Patients invited to participate in Proton Collaborative Group (PCG) Registry and clinical trial of partial breast irradiation in early-stage breast cancer

California Protons Cancer Therapy Center Begins Breast Cancer Study Enrollment

April 25, 2019 — California Protons Cancer Therapy Center announced two major efforts representing significant steps forward in breast cancer treatment research involving its noninvasive, targeted proton therapy. Current California Protons patients as of Feb. 4, 2019, are invited to enroll in the Proton Collaborative Group (PCG) Registry of more than 13,000 patients. Separately, the PCG BRE007-12 Partial Breast Irradiation in early-stage breast cancer clinical trial will enroll around five to eight females per year.

The PCG Registry has been in existence since 2010. It is a prospective tracking study that allows for the collection and analysis of patient information to evaluate the disease process and treatment-related outcomes, thus defining strengths and weaknesses of proton radiation therapy. Qualified patients are invited to enroll in person at their first physician visit during treatment.

The primary objective of the PCG BRE007-12 Partial Breast Irradiation study is to determine freedom from ipsilateral breast recurrences in patients receiving partial breast proton radiation therapy limited to the region of the tumor at three years post-treatment. One of the goals of this study is to determine whether or not limiting radiation to just a portion of the breast is as effective as the traditional treatment of the entire breast. A number of trials have suggested that this “partial breast” approach is every bit as effective as treating the entire breast and may also be less toxic. Performing such partial breast treatments with protons can help to further reduce toxicity by taking advantage of the protons’ ability to be precisely conformed to the target area without giving “spillover” radiation to surrounding healthy tissue such as the lung and heart.

PCG has partnered with 11 proton treatment centers in the U.S., and the data has been used in close to 50 scientific manuscripts, posters and academic presentations to date. PCG research has been presented at 20 medical conferences and has been published in a number of peer-reviewed medical journals.

Both the Patient Registry and the Partial Breast Irradiation Trial are Institutional Review Board (IRB)-approved. These breast cancer trials supplement California Protons Cancer Therapy Center’s ongoing research projects with the University of California San Diego (UCSD) and the Radiation Therapy Oncology Group (RTOG) Foundation 3510 Phase III randomized trial of proton versus photon therapy for patients with nonmetastatic breast cancer receiving comprehensive nodal radiation.

Watch the VIDEO: Whole Versus Partial Radiotherapy for Breast Cancer

For more information: www.californiaprotons.com

Related Content

IBA Gathers Experts on Flash Irradiation During ASTRO
News | Proton Therapy | September 17, 2019
IBA (Ion Beam Applications SA, held its third Victoria Consortium Meeting focusing on Flash irradiation at the 2019...
Noninvasive Radioablation Offers Long-term Benefits to High-risk Heart Arrhythmia Patients
News | Radiation Therapy | September 17, 2019
September 17, 2019 — Treating high-risk heart patients with a single, high dose of...
Sun Nuclear Presents Portfolio of Independent Radiotherapy QA Solutions at ASTRO 2019

The PlanCheck module now part of SunCheck, automates plan quality checks, validates treatment plans against requirements, and automatically assesses plan performance versus intent.

News | Quality Assurance (QA) | September 16, 2019
At the 2019 American Society for Radiation Oncology (ASTRO) Annual Meeting, running Sept. 15-18 in Chicago, Sun Nuclear...
Varian Unveils Ethos Solution for Adaptive Radiation Therapy
News | Image Guided Radiation Therapy (IGRT) | September 16, 2019
At the 2019 American Society for Radiation Oncology (ASTRO) annual meeting, being held Sept. 15-18 in Chicago, Varian...
Long-term Hormone Therapy Increases Mortality Risk for Low-PSA Men After Prostate Surgery
News | Prostate Cancer | September 16, 2019
Secondary analysis of a recent clinical trial that changed the standard of care for men with recurring prostate cancer...
The Siemens Somatom Go.Sim computed tomography (CT) system for dedicated radiation therapy planning

The Siemens Somatom Go.Sim computed tomography (CT) system for dedicated radiation therapy planning. Image courtesy of Siemens Healthineers.

News | Computed Tomography (CT) | September 15, 2019
Siemens Healthineers debuted two computed tomography (CT) systems dedicated to radiation therapy (RT) planning at the...
Isoray to Spotlight Cesium-131 Advances at ASTRO Annual Meeting
News | Brachytherapy Systems | September 13, 2019
Isoray Inc. announced it will spotlight the growing cancer treatment applications of Cesium-131 brachytherapy at the...
Akesis Galaxy SRS System Receives FDA 510(k) Clearance
Technology | Radiation Therapy | September 13, 2019
The Akesis Galaxy, a gamma stereotactic radiosurgery system (SRS) with continuous 360-degree rotational technology, has...
Philips Showcases Integrated Radiation Oncology Portfolio at ASTRO 2019
News | Radiation Oncology | September 13, 2019
Philips will showcase its integrated radiation oncology portfolio at the American Society of Radiation Oncology (ASTRO...
RefleXion Highlights Novel Approach to Radiotherapy at ASTRO 2019

The RefleXion X1 Machine without the Gantry Cover. The patented technology incorporates PET imaging data, which enables tumors to continuously signal their location. Image courtesy of Reflexion Medical.

News | Radiation Therapy | September 12, 2019
Therapeutic oncology company RefleXion Medical announced it will showcase the RefleXion X1 Machine at the American...